Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Our most advanced molecules are in Phase 3 registrational studies for various cancer indications and we expect our next wave of clinical-stage molecules to come from our inflammation and autoimmune disease programs. Our vision is to leverage our internal small-molecule discovery capabilities to create, develop and commercialize highly differentiated therapies that can have a meaningful impact on patients.
In the company’s own words · 10-K filed Feb 25, 2026 · SEC EDGAR
Business segments
Q2 2026 · $37.0MThe company’s own SEC segment disclosure.
- Access Rights$21.0M57%
- License And Development Services$8.0M22%
- License$4.0M11%
- RD Services$4.0M11%
Arcus Biosciences, Inc. (RCUS) reported revenue of $41M in Q2 2026 (quarter ended June 30, 2026), down 74% from the same quarter a year earlier. That came with net loss of $91M. For the full year FY2025, revenue was $247M (−4.3% year on year) and net income −$353M. Its largest product in 2026-Q2 was Access Rights at $21M, 57% of the disclosed total, just ahead of License And Development Services at 22%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.